Jakks Pacific Announces 2025 Annual Meeting Date and Restructuring of Board of Directors
SANTA MONICA, Calif., March 28, 2025 (GLOBE NEWSWIRE) — JAKKS Pacific, Inc. (NASDAQ: JAKK) today announced that the Board of […]
REE Automotive to Report Fourth-Quarter and Fiscal Year 2024 Financial Results on April 29, 2025
TEL AVIV, Israel, March 28, 2025 (GLOBE NEWSWIRE) — REE Automotive Ltd. (Nasdaq: REE), an automotive technology company that develops […]
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks
Regional Medical Leaders Embrace Daxor’s ezBVA Lab Service Oak Ridge, TN, March 28, 2025 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: […]
Actelis Receives Significant New Orders to Modernize U.S. Military Bases with Rapid Deployment, Cyber Hardened Networking
FREMONT, Calif., March 28, 2025 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader […]
Captivision Unveils New Corporate Branding, Paving the Way for a Transformative Era of Growth
MIAMI, March 28, 2025 (GLOBE NEWSWIRE) — Captivision Inc. (“Captivision” or the “Company”) (NASDAQ: CAPT), today announced a new corporate […]
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage […]
Atlantic International Corp. Reports Strong 2024 Results with Over $442 Million in Revenue; Over 10% Revenue Growth
Company Completes First Quarter Publicly-Traded on Nasdaq Global Market under “ATLN” Announces Strategic Developments and Outlook; Targets $1 to $1.5 […]
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Focused on the evaluation of strategic alternatives Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce […]
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
– Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant […]
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
– Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity […]
